ERBB2 and breast carcinoma: Cross-line therapy has been investigated in diverse tumor types, including the combination of human epidermal growth factor receptor-2 monoclonal antibodies with chemotherapy in breast cancer treatment (15), and the application of anti-angiogenesis therapy alongside chemotherapy for colon and non-small cell lung cancer (16).